BioCryst Pharmaceuticals | BCRX - Current Liabilities


BioCryst Pharmaceuticals reported $208.85M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Chugai Pharma JPY 392.19B 64.49B Jun/2026
Daiichi Sankyo JPY 765.7B 119.32B Jun/2026
DBV Technologies USD 54.3M 2.5M Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novavax USD 330.57M 11.89M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026